http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2380195-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_174898adc234db9836cfd6101f95e88f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2002-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d99aa7ec8328a5fac8eadf8f14312c59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbcac2adaa198f0a6f57f73af4d46883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fffd0871879a4a16a6f8bb5fd16a916 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10e55ed984a38dbbe7d2091a28a59616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29c0822978059f4c410f4dfec7ef7937 |
| publicationDate | 2003-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-2380195-A |
| titleOfInvention | Control of gene expression |
| abstract | A method of suppressing the expression of a selected gene in a eukaryotic cell comprising introducing into the cell (a) a polypeptide comprising a nucleic acid binding portion and a modifying portion comprising a polypeptide of peptidomimetic capapable of modulating covalent modification of nucleic acid or chromatin, or (b) a polynucleotide encoding such a polypeptide. The protein may also comprise a ligand binding portion, and binding of the ligand may modulate binding to nucleic acid. The invention also relates to proteins comprising a nucleic acid binding portion, a modifying portion and a ligand binding portion, wherein the ligand binding and nucleic acid binding portions are derived from different proteins. Preferred fusion proteins utilise the chromatin modifying domain of promyelocytic leukaemia zinc finger (PLZF) fused to the DNA- and/or ligand-binding domains of the oestrogen or androgen receptors. They may be used for the treatment of, for example, breast or prostate cancer. |
| priorityDate | 2001-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 453.